These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9746788)

  • 1. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease.
    Murray PG; Constandinou CM; Crocker J; Young LS; Ambinder RF
    Blood; 1998 Oct; 92(7):2477-83. PubMed ID: 9746788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coexpression of major histocompatibility complex class I and LMP1 in Epstein-Barr virus-positive Hodgkin's lymphoma in a pediatric age group.
    Aybar A; Krause JR
    Microsc Res Tech; 2005 Nov; 68(3-4):247-9. PubMed ID: 16276512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition.
    Lee SP; Constandinou CM; Thomas WA; Croom-Carter D; Blake NW; Murray PG; Crocker J; Rickinson AB
    Blood; 1998 Aug; 92(3):1020-30. PubMed ID: 9680372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.
    Khanna R; Burrows SR; Moss DJ; Silins SL
    J Virol; 1996 Aug; 70(8):5357-62. PubMed ID: 8764046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
    Lee SP; Thomas WA; Murray RJ; Khanim F; Kaur S; Young LS; Rowe M; Kurilla M; Rickinson AB
    J Virol; 1993 Dec; 67(12):7428-35. PubMed ID: 7693972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
    Khanna R; Burrows SR; Nicholls J; Poulsen LM
    Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
    Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
    Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.
    Lautscham G; Mayrhofer S; Taylor G; Haigh T; Leese A; Rickinson A; Blake N
    J Exp Med; 2001 Oct; 194(8):1053-68. PubMed ID: 11602636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of HLA-A*02 antigen status in Hodgkin's disease and analysis of an HLA-A*02-restricted epitope of the Epstein-Barr virus LMP-2 protein.
    Bryden H; MacKenzie J; Andrew L; Alexander FE; Angus B; Krajewski AS; Armstrong AA; Gray D; Cartwright RA; Kane E; Wright DH; Taylor P; Jarrett RF
    Int J Cancer; 1997 Aug; 72(4):614-8. PubMed ID: 9259400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2.
    Lee SP; Thomas WA; Blake NW; Rickinson AB
    Eur J Immunol; 1996 Aug; 26(8):1875-83. PubMed ID: 8765034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease.
    Sing AP; Ambinder RF; Hong DJ; Jensen M; Batten W; Petersdorf E; Greenberg PD
    Blood; 1997 Mar; 89(6):1978-86. PubMed ID: 9058719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin's disease.
    Oudejans JJ; Jiwa NM; Kummer JA; Horstman A; Vos W; Baak JP; Kluin PM; van der Valk P; Walboomers JM; Meijer CJ
    Blood; 1996 May; 87(9):3844-51. PubMed ID: 8611711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and analysis of two strongly transforming isoforms of the Epstein-Barr-Virus(EBV)-encoded latent membrane protein-1 (LMP1) from a single Hodgkin's lymphoma.
    Mehl AM; Fischer N; Rowe M; Hartmann F; Daus H; Trümper L; Pfreundschuh M; Müller-Lantzsch N; Grässer FA
    Int J Cancer; 1998 Apr; 76(2):194-200. PubMed ID: 9537580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma.
    Jones K; Wockner L; Brennan RM; Keane C; Chattopadhyay PK; Roederer M; Price DA; Cole DK; Hassan B; Beck K; Gottlieb D; Ritchie DS; Seymour JF; Vari F; Crooks P; Burrows SR; Gandhi MK
    Clin Exp Immunol; 2016 Feb; 183(2):206-20. PubMed ID: 26422112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus in Hodgkin's disease: more than just an innocent bystander.
    Oudejans JJ; Jiwa NM; Meijer CJ
    J Pathol; 1997 Apr; 181(4):353-6. PubMed ID: 9196428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells.
    Deacon EM; Pallesen G; Niedobitek G; Crocker J; Brooks L; Rickinson AB; Young LS
    J Exp Med; 1993 Feb; 177(2):339-49. PubMed ID: 8381153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
    Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
    J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
    Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
    Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus positivity in Hodgkin's disease does not correlate with an HLA A2-negative phenotype.
    Poppema S; Visser L
    Cancer; 1994 Jun; 73(12):3059-63. PubMed ID: 7515326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.